nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Cisapride—Gefitinib—lung cancer	0.76	1	CrCrCtD
Metoclopramide—CYP2D6—Gefitinib—lung cancer	0.00411	0.32	CbGbCtD
Metoclopramide—CYP2D6—Vinorelbine—lung cancer	0.00317	0.246	CbGbCtD
Metoclopramide—CYP2D6—Erlotinib—lung cancer	0.00243	0.189	CbGbCtD
Metoclopramide—CYP2D6—Vinblastine—lung cancer	0.00195	0.152	CbGbCtD
Metoclopramide—CYP2D6—Doxorubicin—lung cancer	0.0012	0.0932	CbGbCtD
Metoclopramide—Sunitinib—DAPK1—lung cancer	0.00114	0.147	CrCbGaD
Metoclopramide—Sunitinib—STK11—lung cancer	0.000995	0.129	CrCbGaD
Metoclopramide—Sunitinib—AXL—lung cancer	0.000943	0.122	CrCbGaD
Metoclopramide—Sunitinib—MAP2K1—lung cancer	0.000802	0.104	CrCbGaD
Metoclopramide—Sunitinib—FGR—lung cancer	0.000802	0.104	CrCbGaD
Metoclopramide—Sunitinib—FGFR1—lung cancer	0.000598	0.0773	CrCbGaD
Metoclopramide—Sunitinib—ALK—lung cancer	0.000571	0.0739	CrCbGaD
Metoclopramide—Sunitinib—FLT1—lung cancer	0.000571	0.0739	CrCbGaD
Metoclopramide—Sunitinib—KDR—lung cancer	0.000358	0.0463	CrCbGaD
Metoclopramide—Cisapride—CYP2A6—lung cancer	0.000352	0.0455	CrCbGaD
Metoclopramide—Sunitinib—KIT—lung cancer	0.000338	0.0437	CrCbGaD
Metoclopramide—Rash—Teniposide—lung cancer	0.000236	0.00212	CcSEcCtD
Metoclopramide—Dermatitis—Teniposide—lung cancer	0.000235	0.00212	CcSEcCtD
Metoclopramide—Feeling abnormal—Vinblastine—lung cancer	0.000235	0.00212	CcSEcCtD
Metoclopramide—Headache—Teniposide—lung cancer	0.000234	0.00211	CcSEcCtD
Metoclopramide—Bronchospasm—Docetaxel—lung cancer	0.000234	0.0021	CcSEcCtD
Metoclopramide—Flushing—Cisplatin—lung cancer	0.000232	0.00209	CcSEcCtD
Metoclopramide—Tachycardia—Vinorelbine—lung cancer	0.000231	0.00208	CcSEcCtD
Metoclopramide—Muscle spasms—Irinotecan—lung cancer	0.00023	0.00207	CcSEcCtD
Metoclopramide—Bradycardia—Paclitaxel—lung cancer	0.000228	0.00206	CcSEcCtD
Metoclopramide—Feeling abnormal—Topotecan—lung cancer	0.000228	0.00206	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—lung cancer	0.000224	0.00202	CcSEcCtD
Metoclopramide—Neutropenia—Docetaxel—lung cancer	0.000222	0.002	CcSEcCtD
Metoclopramide—Nausea—Teniposide—lung cancer	0.000222	0.002	CcSEcCtD
Metoclopramide—Hypotension—Vinorelbine—lung cancer	0.000221	0.00199	CcSEcCtD
Metoclopramide—Urticaria—Topotecan—lung cancer	0.00022	0.00198	CcSEcCtD
Metoclopramide—Body temperature increased—Topotecan—lung cancer	0.000219	0.00197	CcSEcCtD
Metoclopramide—Body temperature increased—Erlotinib—lung cancer	0.000217	0.00195	CcSEcCtD
Metoclopramide—Visual impairment—Paclitaxel—lung cancer	0.000216	0.00195	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—lung cancer	0.000215	0.00193	CcSEcCtD
Metoclopramide—Leukopenia—Irinotecan—lung cancer	0.000214	0.00193	CcSEcCtD
Metoclopramide—Flushing—Etoposide—lung cancer	0.000212	0.00191	CcSEcCtD
Metoclopramide—Dyspnoea—Vinorelbine—lung cancer	0.000211	0.0019	CcSEcCtD
Metoclopramide—Hypersensitivity—Vinblastine—lung cancer	0.00021	0.00189	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—lung cancer	0.000209	0.00188	CcSEcCtD
Metoclopramide—Muscle spasms—Cisplatin—lung cancer	0.000209	0.00188	CcSEcCtD
Metoclopramide—Leukopenia—Gemcitabine—lung cancer	0.000209	0.00188	CcSEcCtD
Metoclopramide—Flushing—Paclitaxel—lung cancer	0.000208	0.00188	CcSEcCtD
Metoclopramide—Hypertension—Irinotecan—lung cancer	0.000207	0.00186	CcSEcCtD
Metoclopramide—Jaundice—Docetaxel—lung cancer	0.000207	0.00186	CcSEcCtD
Metoclopramide—Asthenia—Vinblastine—lung cancer	0.000205	0.00184	CcSEcCtD
Metoclopramide—Fatigue—Vinorelbine—lung cancer	0.000204	0.00184	CcSEcCtD
Metoclopramide—Hypersensitivity—Topotecan—lung cancer	0.000204	0.00184	CcSEcCtD
Metoclopramide—Tremor—Cisplatin—lung cancer	0.000204	0.00183	CcSEcCtD
Metoclopramide—Hypertension—Gemcitabine—lung cancer	0.000201	0.00181	CcSEcCtD
Metoclopramide—Asthenia—Topotecan—lung cancer	0.000199	0.00179	CcSEcCtD
Metoclopramide—Agranulocytosis—Docetaxel—lung cancer	0.000198	0.00178	CcSEcCtD
Metoclopramide—Confusional state—Irinotecan—lung cancer	0.000197	0.00178	CcSEcCtD
Metoclopramide—Asthenia—Erlotinib—lung cancer	0.000197	0.00177	CcSEcCtD
Metoclopramide—Oedema—Irinotecan—lung cancer	0.000195	0.00176	CcSEcCtD
Metoclopramide—Feeling abnormal—Vinorelbine—lung cancer	0.000195	0.00176	CcSEcCtD
Metoclopramide—Diarrhoea—Vinblastine—lung cancer	0.000195	0.00176	CcSEcCtD
Metoclopramide—Leukopenia—Cisplatin—lung cancer	0.000195	0.00175	CcSEcCtD
Metoclopramide—Muscle spasms—Etoposide—lung cancer	0.000192	0.00173	CcSEcCtD
Metoclopramide—Oedema—Gemcitabine—lung cancer	0.00019	0.00171	CcSEcCtD
Metoclopramide—Nervousness—Paclitaxel—lung cancer	0.00019	0.00171	CcSEcCtD
Metoclopramide—Diarrhoea—Topotecan—lung cancer	0.00019	0.00171	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—lung cancer	0.000189	0.0017	CcSEcCtD
Metoclopramide—Dizziness—Vinblastine—lung cancer	0.000189	0.0017	CcSEcCtD
Metoclopramide—Convulsion—Cisplatin—lung cancer	0.000188	0.0017	CcSEcCtD
Metoclopramide—Urticaria—Vinorelbine—lung cancer	0.000188	0.0017	CcSEcCtD
Metoclopramide—Muscle spasms—Paclitaxel—lung cancer	0.000188	0.00169	CcSEcCtD
Metoclopramide—Diarrhoea—Erlotinib—lung cancer	0.000188	0.00169	CcSEcCtD
Metoclopramide—Body temperature increased—Vinorelbine—lung cancer	0.000187	0.00169	CcSEcCtD
Metoclopramide—Sunitinib—ABCG2—lung cancer	0.000187	0.0242	CrCbGaD
Metoclopramide—Anxiety—Cisplatin—lung cancer	0.000184	0.00166	CcSEcCtD
Metoclopramide—Visual impairment—Docetaxel—lung cancer	0.000183	0.00165	CcSEcCtD
Metoclopramide—Dizziness—Topotecan—lung cancer	0.000183	0.00165	CcSEcCtD
Metoclopramide—Tremor—Paclitaxel—lung cancer	0.000183	0.00165	CcSEcCtD
Metoclopramide—Hypotension—Irinotecan—lung cancer	0.000183	0.00165	CcSEcCtD
Metoclopramide—Dizziness—Erlotinib—lung cancer	0.000181	0.00163	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—lung cancer	0.00018	0.00162	CcSEcCtD
Metoclopramide—Agitation—Paclitaxel—lung cancer	0.00018	0.00162	CcSEcCtD
Metoclopramide—Headache—Vinblastine—lung cancer	0.000179	0.00161	CcSEcCtD
Metoclopramide—Angioedema—Paclitaxel—lung cancer	0.000178	0.00161	CcSEcCtD
Metoclopramide—Leukopenia—Etoposide—lung cancer	0.000178	0.00161	CcSEcCtD
Metoclopramide—Hypotension—Gemcitabine—lung cancer	0.000178	0.0016	CcSEcCtD
Metoclopramide—Oedema—Cisplatin—lung cancer	0.000177	0.0016	CcSEcCtD
Metoclopramide—Insomnia—Irinotecan—lung cancer	0.000177	0.00159	CcSEcCtD
Metoclopramide—Flushing—Docetaxel—lung cancer	0.000177	0.00159	CcSEcCtD
Metoclopramide—Leukopenia—Paclitaxel—lung cancer	0.000175	0.00157	CcSEcCtD
Metoclopramide—Rash—Topotecan—lung cancer	0.000175	0.00157	CcSEcCtD
Metoclopramide—Hypersensitivity—Vinorelbine—lung cancer	0.000175	0.00157	CcSEcCtD
Metoclopramide—Dermatitis—Topotecan—lung cancer	0.000175	0.00157	CcSEcCtD
Metoclopramide—Dyspnoea—Irinotecan—lung cancer	0.000174	0.00157	CcSEcCtD
Metoclopramide—Somnolence—Irinotecan—lung cancer	0.000174	0.00157	CcSEcCtD
Metoclopramide—Headache—Topotecan—lung cancer	0.000174	0.00156	CcSEcCtD
Metoclopramide—Tachycardia—Cisplatin—lung cancer	0.000173	0.00156	CcSEcCtD
Metoclopramide—Rash—Erlotinib—lung cancer	0.000173	0.00156	CcSEcCtD
Metoclopramide—Dermatitis—Erlotinib—lung cancer	0.000173	0.00156	CcSEcCtD
Metoclopramide—Palpitations—Paclitaxel—lung cancer	0.000173	0.00155	CcSEcCtD
Metoclopramide—Convulsion—Etoposide—lung cancer	0.000173	0.00155	CcSEcCtD
Metoclopramide—Insomnia—Gemcitabine—lung cancer	0.000172	0.00155	CcSEcCtD
Metoclopramide—Hypertension—Etoposide—lung cancer	0.000172	0.00155	CcSEcCtD
Metoclopramide—Headache—Erlotinib—lung cancer	0.000172	0.00155	CcSEcCtD
Metoclopramide—Asthma—Methotrexate—lung cancer	0.000171	0.00154	CcSEcCtD
Metoclopramide—Asthenia—Vinorelbine—lung cancer	0.00017	0.00153	CcSEcCtD
Metoclopramide—Dyspnoea—Gemcitabine—lung cancer	0.00017	0.00153	CcSEcCtD
Metoclopramide—Nausea—Vinblastine—lung cancer	0.000169	0.00153	CcSEcCtD
Metoclopramide—Somnolence—Gemcitabine—lung cancer	0.000169	0.00152	CcSEcCtD
Metoclopramide—Convulsion—Paclitaxel—lung cancer	0.000169	0.00152	CcSEcCtD
Metoclopramide—Hypertension—Paclitaxel—lung cancer	0.000169	0.00152	CcSEcCtD
Metoclopramide—Fatigue—Irinotecan—lung cancer	0.000169	0.00152	CcSEcCtD
Metoclopramide—Hypotension—Cisplatin—lung cancer	0.000166	0.00149	CcSEcCtD
Metoclopramide—Anxiety—Paclitaxel—lung cancer	0.000166	0.00149	CcSEcCtD
Metoclopramide—Nausea—Topotecan—lung cancer	0.000165	0.00148	CcSEcCtD
Metoclopramide—Fatigue—Gemcitabine—lung cancer	0.000164	0.00148	CcSEcCtD
Metoclopramide—Confusional state—Etoposide—lung cancer	0.000164	0.00148	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—lung cancer	0.000163	0.00147	CcSEcCtD
Metoclopramide—Nausea—Erlotinib—lung cancer	0.000163	0.00147	CcSEcCtD
Metoclopramide—Diarrhoea—Vinorelbine—lung cancer	0.000162	0.00146	CcSEcCtD
Metoclopramide—Feeling abnormal—Irinotecan—lung cancer	0.000161	0.00145	CcSEcCtD
Metoclopramide—Confusional state—Paclitaxel—lung cancer	0.000161	0.00145	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—lung cancer	0.00016	0.00144	CcSEcCtD
Metoclopramide—Oedema—Paclitaxel—lung cancer	0.000159	0.00144	CcSEcCtD
Metoclopramide—Muscle spasms—Docetaxel—lung cancer	0.000159	0.00143	CcSEcCtD
Metoclopramide—Tachycardia—Etoposide—lung cancer	0.000159	0.00143	CcSEcCtD
Metoclopramide—Dyspnoea—Cisplatin—lung cancer	0.000158	0.00143	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—lung cancer	0.000158	0.00142	CcSEcCtD
Metoclopramide—Feeling abnormal—Gemcitabine—lung cancer	0.000157	0.00141	CcSEcCtD
Metoclopramide—Dizziness—Vinorelbine—lung cancer	0.000157	0.00141	CcSEcCtD
Metoclopramide—Tachycardia—Paclitaxel—lung cancer	0.000156	0.0014	CcSEcCtD
Metoclopramide—Body temperature increased—Irinotecan—lung cancer	0.000155	0.00139	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—lung cancer	0.000153	0.00138	CcSEcCtD
Metoclopramide—Depression—Methotrexate—lung cancer	0.000152	0.00137	CcSEcCtD
Metoclopramide—Hypotension—Etoposide—lung cancer	0.000152	0.00137	CcSEcCtD
Metoclopramide—Body temperature increased—Gemcitabine—lung cancer	0.000151	0.00136	CcSEcCtD
Metoclopramide—Rash—Vinorelbine—lung cancer	0.000149	0.00135	CcSEcCtD
Metoclopramide—Dermatitis—Vinorelbine—lung cancer	0.000149	0.00134	CcSEcCtD
Metoclopramide—Hypotension—Paclitaxel—lung cancer	0.000149	0.00134	CcSEcCtD
Metoclopramide—Headache—Vinorelbine—lung cancer	0.000148	0.00134	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—lung cancer	0.000148	0.00134	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—lung cancer	0.000148	0.00133	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—lung cancer	0.000146	0.00132	CcSEcCtD
Metoclopramide—Feeling abnormal—Cisplatin—lung cancer	0.000146	0.00132	CcSEcCtD
Metoclopramide—Dyspnoea—Etoposide—lung cancer	0.000145	0.00131	CcSEcCtD
Metoclopramide—Somnolence—Etoposide—lung cancer	0.000145	0.0013	CcSEcCtD
Metoclopramide—Insomnia—Paclitaxel—lung cancer	0.000144	0.0013	CcSEcCtD
Metoclopramide—Hypersensitivity—Irinotecan—lung cancer	0.000144	0.0013	CcSEcCtD
Metoclopramide—Convulsion—Docetaxel—lung cancer	0.000143	0.00129	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—lung cancer	0.000143	0.00129	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—lung cancer	0.000142	0.00128	CcSEcCtD
Metoclopramide—Dyspnoea—Paclitaxel—lung cancer	0.000142	0.00128	CcSEcCtD
Metoclopramide—Somnolence—Paclitaxel—lung cancer	0.000142	0.00128	CcSEcCtD
Metoclopramide—Nausea—Vinorelbine—lung cancer	0.000141	0.00127	CcSEcCtD
Metoclopramide—Body temperature increased—Cisplatin—lung cancer	0.00014	0.00126	CcSEcCtD
Metoclopramide—Asthenia—Irinotecan—lung cancer	0.00014	0.00126	CcSEcCtD
Metoclopramide—Fatigue—Etoposide—lung cancer	0.00014	0.00126	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—lung cancer	0.000139	0.00125	CcSEcCtD
Metoclopramide—Fatigue—Paclitaxel—lung cancer	0.000137	0.00124	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—lung cancer	0.000137	0.00123	CcSEcCtD
Metoclopramide—Asthenia—Gemcitabine—lung cancer	0.000137	0.00123	CcSEcCtD
Metoclopramide—Confusional state—Docetaxel—lung cancer	0.000136	0.00123	CcSEcCtD
Metoclopramide—Oedema—Docetaxel—lung cancer	0.000135	0.00122	CcSEcCtD
Metoclopramide—Feeling abnormal—Etoposide—lung cancer	0.000134	0.00121	CcSEcCtD
Metoclopramide—Diarrhoea—Irinotecan—lung cancer	0.000134	0.0012	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—lung cancer	0.000132	0.00119	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—lung cancer	0.000132	0.00119	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—lung cancer	0.000132	0.00119	CcSEcCtD
Metoclopramide—Feeling abnormal—Paclitaxel—lung cancer	0.000131	0.00118	CcSEcCtD
Metoclopramide—Hypersensitivity—Cisplatin—lung cancer	0.000131	0.00118	CcSEcCtD
Metoclopramide—Diarrhoea—Gemcitabine—lung cancer	0.00013	0.00117	CcSEcCtD
Metoclopramide—Dizziness—Irinotecan—lung cancer	0.000129	0.00116	CcSEcCtD
Metoclopramide—Urticaria—Etoposide—lung cancer	0.000129	0.00116	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—lung cancer	0.000129	0.00116	CcSEcCtD
Metoclopramide—Body temperature increased—Etoposide—lung cancer	0.000129	0.00116	CcSEcCtD
Metoclopramide—Asthenia—Cisplatin—lung cancer	0.000127	0.00115	CcSEcCtD
Metoclopramide—Urticaria—Paclitaxel—lung cancer	0.000127	0.00114	CcSEcCtD
Metoclopramide—Hypotension—Docetaxel—lung cancer	0.000126	0.00114	CcSEcCtD
Metoclopramide—Body temperature increased—Paclitaxel—lung cancer	0.000126	0.00113	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—lung cancer	0.000123	0.00111	CcSEcCtD
Metoclopramide—Rash—Irinotecan—lung cancer	0.000123	0.00111	CcSEcCtD
Metoclopramide—Dermatitis—Irinotecan—lung cancer	0.000123	0.00111	CcSEcCtD
Metoclopramide—Headache—Irinotecan—lung cancer	0.000122	0.0011	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—lung cancer	0.000122	0.0011	CcSEcCtD
Metoclopramide—Diarrhoea—Cisplatin—lung cancer	0.000121	0.00109	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—lung cancer	0.000121	0.00109	CcSEcCtD
Metoclopramide—Dyspnoea—Docetaxel—lung cancer	0.00012	0.00108	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—lung cancer	0.00012	0.00108	CcSEcCtD
Metoclopramide—Rash—Gemcitabine—lung cancer	0.00012	0.00108	CcSEcCtD
Metoclopramide—Dermatitis—Gemcitabine—lung cancer	0.00012	0.00108	CcSEcCtD
Metoclopramide—Hypersensitivity—Etoposide—lung cancer	0.00012	0.00108	CcSEcCtD
Metoclopramide—Headache—Gemcitabine—lung cancer	0.000119	0.00107	CcSEcCtD
Metoclopramide—Hypersensitivity—Paclitaxel—lung cancer	0.000117	0.00106	CcSEcCtD
Metoclopramide—Asthenia—Etoposide—lung cancer	0.000117	0.00105	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—lung cancer	0.000116	0.00105	CcSEcCtD
Metoclopramide—Nausea—Irinotecan—lung cancer	0.000116	0.00105	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—lung cancer	0.000114	0.00103	CcSEcCtD
Metoclopramide—Asthenia—Paclitaxel—lung cancer	0.000114	0.00103	CcSEcCtD
Metoclopramide—Nausea—Gemcitabine—lung cancer	0.000113	0.00102	CcSEcCtD
Metoclopramide—Rash—Cisplatin—lung cancer	0.000112	0.00101	CcSEcCtD
Metoclopramide—Dermatitis—Cisplatin—lung cancer	0.000112	0.00101	CcSEcCtD
Metoclopramide—Feeling abnormal—Docetaxel—lung cancer	0.000111	0.001	CcSEcCtD
Metoclopramide—Diarrhoea—Etoposide—lung cancer	0.000111	0.001	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—lung cancer	0.00011	0.000992	CcSEcCtD
Metoclopramide—Diarrhoea—Paclitaxel—lung cancer	0.000109	0.000982	CcSEcCtD
Metoclopramide—Dizziness—Etoposide—lung cancer	0.000108	0.000968	CcSEcCtD
Metoclopramide—Body temperature increased—Docetaxel—lung cancer	0.000107	0.000962	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—lung cancer	0.000107	0.000962	CcSEcCtD
Metoclopramide—Dizziness—Paclitaxel—lung cancer	0.000105	0.000949	CcSEcCtD
Metoclopramide—Nausea—Cisplatin—lung cancer	0.000105	0.000949	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—lung cancer	0.000103	0.000931	CcSEcCtD
Metoclopramide—Rash—Etoposide—lung cancer	0.000103	0.000923	CcSEcCtD
Metoclopramide—Dermatitis—Etoposide—lung cancer	0.000102	0.000922	CcSEcCtD
Metoclopramide—Headache—Etoposide—lung cancer	0.000102	0.000917	CcSEcCtD
Metoclopramide—Rash—Paclitaxel—lung cancer	0.000101	0.000905	CcSEcCtD
Metoclopramide—Dermatitis—Paclitaxel—lung cancer	0.0001	0.000904	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—lung cancer	0.0001	0.000904	CcSEcCtD
Metoclopramide—Headache—Paclitaxel—lung cancer	9.99e-05	0.000899	CcSEcCtD
Metoclopramide—Hypersensitivity—Docetaxel—lung cancer	9.96e-05	0.000897	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—lung cancer	9.93e-05	0.000895	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—lung cancer	9.82e-05	0.000884	CcSEcCtD
Metoclopramide—Asthenia—Docetaxel—lung cancer	9.69e-05	0.000873	CcSEcCtD
Metoclopramide—Nausea—Etoposide—lung cancer	9.66e-05	0.00087	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—lung cancer	9.5e-05	0.000855	CcSEcCtD
Metoclopramide—Nausea—Paclitaxel—lung cancer	9.47e-05	0.000853	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—lung cancer	9.25e-05	0.000833	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—lung cancer	9.25e-05	0.000833	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—lung cancer	9.13e-05	0.000822	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—lung cancer	9.1e-05	0.00082	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—lung cancer	8.95e-05	0.000806	CcSEcCtD
Metoclopramide—Dizziness—Docetaxel—lung cancer	8.94e-05	0.000805	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—lung cancer	8.92e-05	0.000803	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—lung cancer	8.81e-05	0.000793	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—lung cancer	8.77e-05	0.00079	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—lung cancer	8.68e-05	0.000782	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—lung cancer	8.66e-05	0.00078	CcSEcCtD
Metoclopramide—Rash—Docetaxel—lung cancer	8.52e-05	0.000767	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—lung cancer	8.51e-05	0.000767	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—lung cancer	8.5e-05	0.000766	CcSEcCtD
Metoclopramide—Headache—Docetaxel—lung cancer	8.46e-05	0.000762	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—lung cancer	8.43e-05	0.000759	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—lung cancer	8.4e-05	0.000756	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—lung cancer	8.23e-05	0.000741	CcSEcCtD
Metoclopramide—Nausea—Docetaxel—lung cancer	8.03e-05	0.000723	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—lung cancer	8.03e-05	0.000723	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—lung cancer	7.88e-05	0.00071	CcSEcCtD
Metoclopramide—Sunitinib—ABCB1—lung cancer	7.79e-05	0.0101	CrCbGaD
Metoclopramide—Urticaria—Methotrexate—lung cancer	7.74e-05	0.000697	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—lung cancer	7.7e-05	0.000693	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—lung cancer	7.63e-05	0.000687	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—lung cancer	7.52e-05	0.000677	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—lung cancer	7.5e-05	0.000675	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—lung cancer	7.27e-05	0.000655	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—lung cancer	7.18e-05	0.000646	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—lung cancer	6.99e-05	0.000629	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—lung cancer	6.95e-05	0.000626	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—lung cancer	6.7e-05	0.000603	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—lung cancer	6.67e-05	0.0006	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—lung cancer	6.66e-05	0.0006	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—lung cancer	6.44e-05	0.00058	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—lung cancer	6.21e-05	0.00056	CcSEcCtD
Metoclopramide—Rash—Methotrexate—lung cancer	6.14e-05	0.000553	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—lung cancer	6.13e-05	0.000553	CcSEcCtD
Metoclopramide—Headache—Methotrexate—lung cancer	6.1e-05	0.000549	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—lung cancer	6.05e-05	0.000545	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—lung cancer	5.78e-05	0.000521	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—lung cancer	5.77e-05	0.00052	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—lung cancer	5.58e-05	0.000502	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—lung cancer	5.32e-05	0.000479	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—lung cancer	5.31e-05	0.000478	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—lung cancer	5.28e-05	0.000476	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—lung cancer	5.01e-05	0.000451	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—EP300—lung cancer	1.11e-05	0.000103	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—POMC—lung cancer	1.11e-05	0.000103	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—RAF1—lung cancer	1.11e-05	0.000103	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GNG11—lung cancer	1.1e-05	0.000102	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—lung cancer	1.1e-05	0.000102	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—lung cancer	1.09e-05	0.000101	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUNB—lung cancer	1.09e-05	0.000101	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CB—lung cancer	1.08e-05	0.000101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CG—lung cancer	1.08e-05	0.0001	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—lung cancer	1.07e-05	9.92e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CG—lung cancer	1.06e-05	9.83e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALDOA—lung cancer	1.05e-05	9.74e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CD—lung cancer	1.05e-05	9.72e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—lung cancer	1.04e-05	9.67e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—EP300—lung cancer	1.04e-05	9.67e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB3—lung cancer	1.04e-05	9.6e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—lung cancer	1.03e-05	9.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—POMC—lung cancer	1.03e-05	9.56e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CD—lung cancer	1.03e-05	9.52e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOA3—lung cancer	1.02e-05	9.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STK11—lung cancer	1.01e-05	9.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—POMC—lung cancer	1.01e-05	9.36e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6R—lung cancer	1.01e-05	9.33e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—lung cancer	9.96e-06	9.24e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TERT—lung cancer	9.93e-06	9.2e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCG2—lung cancer	9.92e-06	9.2e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ADCY1—lung cancer	9.92e-06	9.2e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STK11—lung cancer	9.92e-06	9.2e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—lung cancer	9.9e-06	9.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6R—lung cancer	9.84e-06	9.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FOXO3—lung cancer	9.78e-06	9.07e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HPGDS—lung cancer	9.73e-06	9.02e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ENO2—lung cancer	9.73e-06	9.02e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPP2R1B—lung cancer	9.67e-06	8.97e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGFR1—lung cancer	9.64e-06	8.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAP2K1—lung cancer	9.59e-06	8.89e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FOXO3—lung cancer	9.57e-06	8.88e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—lung cancer	9.57e-06	8.87e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CD—lung cancer	9.52e-06	8.83e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HIF1A—lung cancer	9.49e-06	8.8e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—lung cancer	9.47e-06	8.78e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTT1—lung cancer	9.44e-06	8.75e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAP2K1—lung cancer	9.38e-06	8.7e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GCLC—lung cancer	9.33e-06	8.65e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2A6—lung cancer	9.33e-06	8.65e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CD—lung cancer	9.32e-06	8.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AVP—lung cancer	9.17e-06	8.5e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOA1—lung cancer	9.16e-06	8.49e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CB—lung cancer	9.14e-06	8.48e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KDR—lung cancer	9.08e-06	8.42e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AVP—lung cancer	8.97e-06	8.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CB—lung cancer	8.95e-06	8.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ENO1—lung cancer	8.85e-06	8.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1R—lung cancer	8.82e-06	8.18e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—lung cancer	8.78e-06	8.14e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—lung cancer	8.74e-06	8.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HES1—lung cancer	8.67e-06	8.04e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1R—lung cancer	8.64e-06	8.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—lung cancer	8.6e-06	7.97e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—RAF1—lung cancer	8.5e-06	7.88e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HES1—lung cancer	8.48e-06	7.87e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—lung cancer	8.4e-06	7.78e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KIT—lung cancer	8.36e-06	7.75e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CG—lung cancer	8.36e-06	7.75e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APC—lung cancer	8.36e-06	7.75e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—NRAS—lung cancer	8.36e-06	7.75e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—RAF1—lung cancer	8.32e-06	7.72e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CB—lung cancer	8.3e-06	7.7e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGF—lung cancer	8.27e-06	7.67e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—lung cancer	8.24e-06	7.64e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—lung cancer	8.22e-06	7.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CB—lung cancer	8.12e-06	7.53e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—lung cancer	8.01e-06	7.43e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—lung cancer	7.98e-06	7.4e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—POMC—lung cancer	7.96e-06	7.38e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2E1—lung cancer	7.93e-06	7.36e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB3—lung cancer	7.93e-06	7.35e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—BRAF—lung cancer	7.86e-06	7.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NQO1—lung cancer	7.84e-06	7.27e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—lung cancer	7.82e-06	7.25e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—lung cancer	7.81e-06	7.24e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6R—lung cancer	7.77e-06	7.2e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB3—lung cancer	7.76e-06	7.19e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CREBBP—lung cancer	7.75e-06	7.19e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—lung cancer	7.71e-06	7.15e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—lung cancer	7.62e-06	7.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—lung cancer	7.62e-06	7.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—lung cancer	7.6e-06	7.04e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—lung cancer	7.46e-06	6.92e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—lung cancer	7.43e-06	6.89e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAP2K1—lung cancer	7.4e-06	6.86e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR1—lung cancer	7.38e-06	6.84e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CD—lung cancer	7.35e-06	6.82e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—lung cancer	7.28e-06	6.75e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—lung cancer	7.26e-06	6.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR1—lung cancer	7.22e-06	6.69e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—lung cancer	7.2e-06	6.67e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—lung cancer	7.11e-06	6.59e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—STK11—lung cancer	7.07e-06	6.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOA1—lung cancer	7.01e-06	6.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KDR—lung cancer	6.95e-06	6.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOA1—lung cancer	6.86e-06	6.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KDR—lung cancer	6.8e-06	6.3e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—lung cancer	6.73e-06	6.24e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—lung cancer	6.61e-06	6.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MDM2—lung cancer	6.59e-06	6.11e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RAF1—lung cancer	6.56e-06	6.09e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—lung cancer	6.54e-06	6.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—lung cancer	6.49e-06	6.02e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MTOR—lung cancer	6.41e-06	5.94e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CB—lung cancer	6.41e-06	5.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CG—lung cancer	6.4e-06	5.93e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KIT—lung cancer	6.4e-06	5.93e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APC—lung cancer	6.4e-06	5.93e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NRAS—lung cancer	6.4e-06	5.93e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAT—lung cancer	6.37e-06	5.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGF—lung cancer	6.33e-06	5.87e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—lung cancer	6.3e-06	5.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KIT—lung cancer	6.26e-06	5.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APC—lung cancer	6.26e-06	5.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CG—lung cancer	6.26e-06	5.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NRAS—lung cancer	6.26e-06	5.81e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCB1—lung cancer	6.19e-06	5.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGF—lung cancer	6.19e-06	5.74e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—lung cancer	6.16e-06	5.71e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—lung cancer	6.13e-06	5.68e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—lung cancer	6.12e-06	5.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—POMC—lung cancer	6.09e-06	5.65e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—lung cancer	6.08e-06	5.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BRAF—lung cancer	6.02e-06	5.58e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—lung cancer	6.01e-06	5.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—lung cancer	6e-06	5.56e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—POMC—lung cancer	5.96e-06	5.53e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—lung cancer	5.95e-06	5.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6R—lung cancer	5.94e-06	5.51e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CREBBP—lung cancer	5.93e-06	5.5e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—lung cancer	5.89e-06	5.47e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BRAF—lung cancer	5.89e-06	5.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—lung cancer	5.89e-06	5.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—lung cancer	5.86e-06	5.43e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—lung cancer	5.83e-06	5.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6R—lung cancer	5.82e-06	5.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CREBBP—lung cancer	5.81e-06	5.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—lung cancer	5.74e-06	5.32e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JUN—lung cancer	5.73e-06	5.31e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—lung cancer	5.71e-06	5.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A1—lung cancer	5.7e-06	5.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAP2K1—lung cancer	5.66e-06	5.25e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ERCC2—lung cancer	5.65e-06	5.24e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CD—lung cancer	5.63e-06	5.22e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	5.57e-06	5.17e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—lung cancer	5.57e-06	5.16e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1A—lung cancer	5.55e-06	5.15e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAP2K1—lung cancer	5.54e-06	5.14e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—lung cancer	5.54e-06	5.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—lung cancer	5.51e-06	5.11e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CD—lung cancer	5.51e-06	5.11e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	5.45e-06	5.06e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—lung cancer	5.4e-06	5.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—lung cancer	5.39e-06	5e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EP300—lung cancer	5.28e-06	4.9e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SRC—lung cancer	5.14e-06	4.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—lung cancer	5.06e-06	4.69e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MDM2—lung cancer	5.04e-06	4.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RAF1—lung cancer	5.02e-06	4.66e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—lung cancer	5e-06	4.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—lung cancer	4.97e-06	4.61e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—lung cancer	4.95e-06	4.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	4.95e-06	4.59e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRAS—lung cancer	4.94e-06	4.58e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MDM2—lung cancer	4.93e-06	4.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RAF1—lung cancer	4.92e-06	4.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MTOR—lung cancer	4.9e-06	4.55e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CB—lung cancer	4.9e-06	4.55e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA1—lung cancer	4.89e-06	4.53e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—lung cancer	4.86e-06	4.51e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CB—lung cancer	4.8e-06	4.45e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MTOR—lung cancer	4.8e-06	4.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—lung cancer	4.73e-06	4.39e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—lung cancer	4.71e-06	4.37e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—lung cancer	4.68e-06	4.34e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—lung cancer	4.61e-06	4.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—lung cancer	4.6e-06	4.27e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—lung cancer	4.58e-06	4.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—lung cancer	4.55e-06	4.22e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—lung cancer	4.51e-06	4.18e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—lung cancer	4.5e-06	4.18e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—lung cancer	4.5e-06	4.17e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—lung cancer	4.48e-06	4.15e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CG—lung cancer	4.46e-06	4.14e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—lung cancer	4.46e-06	4.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—lung cancer	4.41e-06	4.09e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—lung cancer	4.41e-06	4.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—lung cancer	4.39e-06	4.07e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—lung cancer	4.39e-06	4.07e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JUN—lung cancer	4.38e-06	4.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—lung cancer	4.3e-06	3.98e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUN—lung cancer	4.29e-06	3.98e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—lung cancer	4.26e-06	3.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—lung cancer	4.25e-06	3.94e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POMC—lung cancer	4.25e-06	3.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1A—lung cancer	4.25e-06	3.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—lung cancer	4.24e-06	3.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—lung cancer	4.17e-06	3.87e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1A—lung cancer	4.16e-06	3.85e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—lung cancer	4.15e-06	3.85e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CREBBP—lung cancer	4.14e-06	3.84e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—lung cancer	4.13e-06	3.83e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—lung cancer	4.05e-06	3.75e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EP300—lung cancer	4.04e-06	3.75e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EP300—lung cancer	3.95e-06	3.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SRC—lung cancer	3.93e-06	3.64e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CD—lung cancer	3.92e-06	3.64e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—lung cancer	3.91e-06	3.62e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—lung cancer	3.87e-06	3.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SRC—lung cancer	3.85e-06	3.57e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—lung cancer	3.83e-06	3.55e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—lung cancer	3.79e-06	3.51e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRAS—lung cancer	3.78e-06	3.51e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—lung cancer	3.78e-06	3.5e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—lung cancer	3.75e-06	3.47e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—lung cancer	3.71e-06	3.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRAS—lung cancer	3.7e-06	3.43e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—lung cancer	3.62e-06	3.36e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—lung cancer	3.61e-06	3.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—lung cancer	3.54e-06	3.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—lung cancer	3.52e-06	3.27e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—lung cancer	3.46e-06	3.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—lung cancer	3.45e-06	3.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—lung cancer	3.44e-06	3.19e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CB—lung cancer	3.42e-06	3.17e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—lung cancer	3.39e-06	3.14e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—lung cancer	3.37e-06	3.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—lung cancer	3.25e-06	3.02e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—lung cancer	3.19e-06	2.96e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—lung cancer	3.18e-06	2.95e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—lung cancer	2.99e-06	2.77e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—lung cancer	2.96e-06	2.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—lung cancer	2.93e-06	2.71e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—lung cancer	2.89e-06	2.68e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—lung cancer	2.83e-06	2.62e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—EP300—lung cancer	2.82e-06	2.61e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—lung cancer	2.77e-06	2.56e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—lung cancer	2.71e-06	2.51e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—lung cancer	2.65e-06	2.45e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—lung cancer	2.59e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—lung cancer	2.44e-06	2.26e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—lung cancer	2.39e-06	2.22e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—lung cancer	2.09e-06	1.93e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—lung cancer	1.7e-06	1.58e-05	CbGpPWpGaD
